Cepheid Q2 Revenues Climb 21 Percent, but Miss Analyst Estimates
July 20, 2012
Cepheid Q2 Revenues Climb 21 Percent, but Miss Analyst Estimates
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Spain's Stat-Diagnostica Aims to Market Near-patient IVD System in Europe, US in 2015
May 16, 2013 / PCR Insider - China's Zeesan Biotech Developing Portfolio of Melt Curve MDx Assays after SFDA Approves TB Tests
April 25, 2013 / PCR Insider - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider - Cepheid's Q1 Revenues Increase 19 Percent
April 19, 2013 / GenomeWeb Daily News - On Heels of FDA Approval, Cepheid's Xpert CT/NG Test Performs Well in Multi-Center Clinical Study
March 14, 2013 / PCR Insider